

MEDIA RELEASE EMBARGOED UNTIL 7 JULY 2006

S*BIO DEVELOPS SINGAPORE'S FIRST CLINICAL CANDIDATE FOR CANCER

SB939, its lead novel HDAC inhibitor, is selected for advancement into the clinic

July 7, 2006, Singapore – S*BIO Pte Ltd announced today that it has taken a significant step forward in its drug discovery and development efforts as its lead clinical candidate for cancer moves towards the clinic. This represents a significant achievement for both S*BIO's research and development team and for Singapore, as SB939 is Singapore's first home-grown clinical candidate to be developed as a novel targeted cancer therapy.

S*BIO anticipates that clinical trials of SB939 will commence both in Singapore and in North America in Q1 2007.

In preclinical studies, SB939 demonstrates excellent anti-cancer efficacy. SB939 has the potential to be used as an oral therapy for a variety of human haematological malignancies and solid tumours. SB939, developed in-house by S*BIO, belongs to a novel series of targeted small molecule based anti-cancer agents that inhibit histone deacetylases (HDAC), enzymes that are important regulators of pro-apoptotic factors and proteins involved in cell cycle progression and differentiation.

"With SB939 poised to enter the clinic in Q1 2007, S*BIO has clearly demonstrated its ability to deliver a potential "best-in-class" HDAC inhibitor clinical candidate in less than 12 months. As a company, we are very excited about the success of SB939 and are strongly committed to accelerating its clinical development," commented Dr. Jan-Anders Karlsson, Chief Executive Officer of S*BIO.

Moving forward, S*BIO will aggressively drive other programs towards a similar success, including next generation HDAC inhibitors and a new type of kinase inhibitors, which are targeted to reach preclinical development by the end of 2006.



Company Regn No: 200004639G

About S*BIO Pte Ltd

S*BIO is a privately held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO intends to become a leading fully integrated oncology-focused biotech company in Asia Pacific.

S*BIO has developed a fully integrated state-of-the-art R&D infrastructure and expertise to support its efforts in oncology. In anticipation of delivering its first IND in 2006, S*BIO is building a strong clinical development team and is actively fostering close ties with medical oncology networks in Asia Pacific. The Company is aggressively building a pipeline of internal and in-licensed compounds.

More information about S*BIO can be found at www.sbio.com

###

Any media enquiries may be directed to:

Chan Yiu Lin

PR Consultant, S*BIO

Email: pr@sbio.com

Mobile: (65) 9-765 5897